Tamoxifen: a most unlikely pioneering medicine
暂无分享,去创建一个
[1] G. Beatson. On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.
[2] Stanley Boyd,et al. Oophorectomy for Cancer of the Breast , 1900, The Hospital.
[3] A. Lathrop,et al. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. , 1916, The Journal of cancer research.
[4] A. Lacassagne,et al. Hormonal Pathogenesis of Adenocarcinoma of the Breast , 1936 .
[5] A. Haddow,et al. Influence of Synthetic Oestrogens on Advanced Malignant Disease , 1944, British medical journal.
[6] A. H. Harkness,et al. Oral penicillin in gonorrhoea. , 1946, Lancet.
[7] E. Paterson,et al. SYNTHETIC ŒSTROGENS IN MAMMARY CANCER , 1949 .
[8] E. Paterson,et al. Synthetic oestrogens in mammary cancer. , 1949, Lancet.
[9] L. Lerner,et al. A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. , 1958, Endocrinology.
[10] A. Chobanian,et al. The effects of triparanol (MER-29) in subjects with and without coronary artery disease. , 1960, JAMA.
[11] L. Lerner,et al. Gonadotrophin Inhibiting and Anti-Fecundity Effects of Chloramiphene. ∗ , 1960, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[12] M. Thompson,et al. Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. , 1960, The Journal of biological chemistry.
[13] R. Greenblatt,et al. Induction of ovulation with MRL/41. Preliminary report. , 1961, JAMA.
[14] C. Huggins,et al. Mammary Cancer Induced by a Single Feeding of Polynuclear Hydrocarbons, and its Suppression , 1961, Nature.
[15] Kraft Ro. Triparanol in the treatment of disseminated mammary carcinoma. , 1962 .
[16] R. Laughlin,et al. Cataracts in patients treated with triparanol. , 1962, JAMA.
[17] R. Kraft. Triparanol in the treatment of disseminated mammary carcinoma. , 1962, Cancer chemotherapy reports.
[18] G. Duncan,et al. Antifertility Activities of Two Diphenyl-Dihydronaphthalene Derivatives , 1963 .
[19] C. Griffiths,et al. CLOMIPHENE CITRATE (NSC-35770) IN DISSEMINATED MAMMARY CARCINOMA. , 1964, Cancer chemotherapy reports.
[20] W. Herrmann. [THE INDUCTION OF OVULATION]. , 1964, Gynakologische Rundschau.
[21] Herbst Al,et al. CLOMIPHENE CITRATE (NSC-35770) IN DISSEMINATED MAMMARY CARCINOMA. , 1964 .
[22] G. R. Bedford,et al. Preparation and Identification of cis and trans Isomers of a Substituted Triarylethylene , 1966, Nature.
[23] M. Harper,et al. Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes , 1966, Nature.
[24] M. J. Whitelaw. Clomiphene citrate: experience with 217 patients. Variation in response and unusual reactions. , 1966, Fertility and Sterility.
[25] M. Harper,et al. Mode of action of I.C.I. 46,474 in preventing implantation in rats. , 1967, Journal of Endocrinology.
[26] Clomiphene citrate (Clomid) , 1967 .
[27] K.,et al. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.
[28] B. T. Kilbourn,et al. Identification of isomers of a substituted triarylethylene: the crystal structure of 1-p-(2-dimethylaminoethoxyphenyl)-1,2-cis-diphenylbut-1-ene hydrobromide , 1968 .
[29] A. P. Labhsetwar. Role of estrogens in ovulation: A study using the estrogen-antagonist, I.C.I. 46,474. , 1970, Endocrinology.
[30] A. P. Labhsetwar. Role of Oestrogen in Spontaneous Ovulation demonstrated by Use of an Antagonist of Oestrogen, ICI 46,474 , 1970, Nature.
[31] A. Klopper,et al. Medazepam Compared with Amylobarbitone in Treatment of Anxiety , 1971, British medical journal.
[32] I. Todd,et al. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.
[33] E. Jensen,et al. Estrogen receptors and breast cancer response to adrenalectomy. , 1971, National Cancer Institute monograph.
[34] A. P. Labhsetwar. Effects of an antioestrogen on the corpus luteum of rabbits and rats. , 1971, Journal of reproduction and fertility.
[35] A. P. Labhsetwar. Role of estrogens in spontaneous ovulation: evidence for the positive feedback in hamsters. , 1972, Endocrinology.
[36] J. S. Beck,et al. TREATMENT OF MENOMETRORRHAGIA WITH AN ANTI‐OESTROGEN , 1972, Clinical endocrinology.
[37] J. Woodburn,et al. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. , 1972, The Journal of endocrinology.
[38] J. Williamson,et al. THE INDUCTION OF OVULATION BY TAMOXIFEN , 1973, The Journal of obstetrics and gynaecology of the British Commonwealth.
[39] H. Ward. Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels , 1973, British medical journal.
[40] D. Macourt,et al. A NEW SYNTHETIC AGENT FOR THE INDUCTION OF OVULATION* , 1974, The Medical journal of Australia.
[41] H. Bloom,et al. Antioestrogens in Treatment of Breast Cancer: Value of Nafoxidine in 52 Advanced Cases , 1974, British medical journal.
[42] M. Lippman,et al. Oestrogen-responsive human breast cancer in long term tissue culture , 1975, Nature.
[43] A. Klopper,et al. ANTIOESTROGENS: A REVIEW , 1975, Clinical endocrinology.
[44] V. Jordan,et al. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. , 1975, European journal of cancer.
[45] R. Nicholson,et al. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. , 1975, European journal of cancer.
[46] V. Jordan,et al. Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. , 1976, The Journal of endocrinology.
[47] S. Ernst,et al. Stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure-activity relationships. , 1976, Journal of pharmaceutical sciences.
[48] D. Gordon. WOODPECKERS' TONGUES , 1976, The Lancet.
[49] V. Jordan,et al. Tamoxifen as an anti-tumour agent: effect on oestrogen binding. , 1976, The Journal of endocrinology.
[50] S. Legha,et al. Nafoxidine–‐an antiestrogen for the treatment of breast cancer , 1976, Cancer.
[51] V. Jordan. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. , 1976, European journal of cancer.
[52] D A Chamberlain,et al. The Brighton resuscitation ambulances: a continuing experiment in prehospital care by ambulance staff. , 1976, British medical journal.
[53] J. Evans,et al. The induction of ovulation. , 1976, American journal of obstetrics and gynecology.
[54] V. Jordan,et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, Journal of Endocrinology.
[55] D. Kiang,et al. Tamoxifen (antiestrogen) therapy in advanced breast cancer. , 1977, Annals of internal medicine.
[56] I. Todd. Adjuvant Therapy of Cancer , 1978, British Journal of Cancer.
[57] V. Jordan,et al. EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS , 1980, British journal of pharmacology.
[58] V. Jordan,et al. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. , 1980, European journal of cancer.
[59] J. deBoever,et al. Oestrogen receptors in human breast cancer. , 1980 .
[60] V. Jordan,et al. Pharmacology of tamoxifen in laboratory animals. , 1980, Cancer treatment reports.
[61] J. Ingle,et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.
[62] R. Deitch. After the Trial at Leicester , 1981, The Lancet.
[63] V. Kyle,et al. PROSTAGLANDIN E1 AND PERIPHERAL VASCULAR DISEASE , 1983, The Lancet.
[64] K. McPherson,et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. , 1983, Lancet.
[65] Michael Baum,et al. IMPROVED SURVIVAL AMONGST PATIENTS TREATED WITH ADJUVANT TAMOXIFEN AFTER MASTECTOMY FOR EARLY BREAST CANCER , 1983, The Lancet.
[66] E. Bäumler,et al. Paul Ehrlich, scientist for life , 1984 .
[67] P. Satyaswaroop,et al. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. , 1984, Cancer research.
[68] P. Draca,et al. [Postcoital contraception]. , 1985, Medicinski pregled.
[69] S. Robinson,et al. Species-specific pharmacology of antiestrogens: role of metabolism. , 1987, Federation proceedings.
[70] V. Jordan,et al. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. , 1987, Cancer research.
[71] C. Osborne,et al. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. , 1987, European journal of cancer & clinical oncology.
[72] S. Robinson,et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.
[73] G. Hortobagyi,et al. Phase II evaluation of Ly156758 in metastatic breast cancer. , 1988, Oncology.
[74] V. Jordan,et al. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.
[75] T. Powles,et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. , 1989, British Journal of Cancer.
[76] Nils Wilking,et al. ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.
[77] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[78] Stephen E. Jones,et al. Adjuvant Therapy of Cancer , 1990 .
[79] A. Wakeling,et al. A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.
[80] D. DeMets,et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. , 1991, Annals of internal medicine.
[81] V. Jordan,et al. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. , 1991, Journal of the National Cancer Institute.
[82] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[83] T. Orton,et al. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. , 1993, Cancer research.
[84] M. Carcangiu. Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.
[85] C. Redmond,et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.
[86] V. Jordan. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[88] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[89] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[90] V. Jordan. Designer estrogens. , 1998, Scientific American.
[91] W. Gradishar,et al. Tamoxifen and contralateral breast cancer. , 1999, Journal of the American College of Surgeons.
[92] T. Powles. COMMENT ON: TAMOXIFEN FOR PREVENTION OF BREAST CANCER : REPORT OF THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT P-1 STUDY , 1999 .
[93] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[94] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[95] S. Cummings,et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .
[96] V. Jordan,et al. Selective estrogen receptor modulation: a personal perspective. , 2001, Cancer research.
[97] J. Bryant,et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.
[98] C K Osborne,et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] A. Howell,et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] J. Mackay. IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-1) - a randomised prevention trial , 2002 .
[101] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[102] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[103] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[104] J. Andersen,et al. Oestrogen receptors in human breast cancer , 1982, Virchows Archiv A.
[105] M. Baum,et al. Alternative mechanisms of action of anti-oestrogens , 2004, Breast Cancer Research and Treatment.
[106] J. Lindgren,et al. Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.
[107] V. Jordan,et al. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole , 1988, Breast Cancer Research and Treatment.